NDA 213586 · Teva
Uzedy
Risperidone · Subcutaneous · Atypical Antipsychotic
Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Apr 28, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
514
127 Phase 3, 14 recruiting
FAERS reports
64,028
49,562 serious, 5,886 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for the treatment of patients with dementia-related psychosis and has not been studied in this patient population [see Warnings and Precautions ( 5.1 )]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for use in patients with dementia-related psychosis. ( 5.1 )
What it is approved for
From the label in effect Oct 31, 2025.
UZEDY is an atypical antipsychotic indicated: for the treatment of schizophrenia in adults. ( 1.1 ) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. ( 1.2 ) 1.1 Schizophrenia UZEDY is indicated for the treatment of schizophrenia in adults . 1.2 Bipolar Disorder UZEDY is indicated as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder in adults.
Mechanism: The mechanism of action of risperidone, for the listed indications, is unclear. The drug’s therapeutic activity could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone (paliperidone) [see Clinical Pharmacology ( 12.3 )] . Antagonism at receptors other than D 2 and 5HT 2 may explain some of the other effects of risperidone.
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 2025 Supplement 8 · Efficacy LabelLetter
- Apr 28, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
7 products under this application
- UZEDY · RISPERIDONE 200MG/0.56ML (200MG/0.56ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- UZEDY · RISPERIDONE 125MG/0.35ML (125MG/0.35ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- UZEDY · RISPERIDONE 75MG/0.21ML (75MG/0.21ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- UZEDY · RISPERIDONE 250MG/0.7ML (250MG/0.7ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- UZEDY · RISPERIDONE 150MG/0.42ML (150MG/0.42ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- UZEDY · RISPERIDONE 100MG/0.28ML (100MG/0.28ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
- UZEDY · RISPERIDONE 50MG/0.14ML (50MG/0.14ML) · SUSPENSION, EXTENDED RELEASE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Risperidone" as an intervention, any sponsor and status, largest first.
- Safety Study of Sertindole Versus Risperidone Under Normal Conditions of UsePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT00856583 · 9,809 participants · Start Jul 2002 · Primary completion Feb 2008
Drug: Sertindole; Risperidone · For: Schizophrenia
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia IndividualsStatus unknown
Tianjin Medical University General HospitalAcademic, hospital or other
NCT03790085 · 2,700 participants (planned) · Start Sep 1, 2018 · Primary completion Jun 30, 2020
Drug: Risperidone; Olanzapine and 1 more · For: Schizophrenia; Major Depressive Disorder; Anxiety Disorders
Sites: Tianjin, China
- Metabolic Profile and Anthropometric Changes in SchizophreniaPivotal-lookingCompleted
Central Institute of Psychiatry, Ranchi, IndiaAcademic, hospital or other
NCT00534183 · 2,006 participants · Start Jun 2006
Drug: Olanzapine; Risperidone and 1 more · For: Metabolic Syndrome; Diabetes; Obesity
Sites: Ranchi, India
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaPivotal-lookingCompleted
Janssen, LPJohnson & Johnson (Janssen) (JNJ)
NCT00249119 · 1,579 participants
Drug: risperidone · For: Schizophrenia; Psychotic Disorder
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- gynaecomastia9,330
- off label use5,729
- drug ineffective5,316
- weight increased4,408
- drug interaction3,245
- product use in unapproved indication2,988
- emotional disorder2,879
- abnormal weight gain2,864
- condition aggravated2,411
- somnolence2,323
- toxicity to various agents2,293
- extrapyramidal disorder2,091
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 400 |
| 2005 | 506 |
| 2006 | 592 |
| 2007 | 580 |
| 2008 | 698 |
| 2009 | 1,200 |
| 2010 | 1,157 |
| 2011 | 1,587 |
| 2012 | 1,884 |
| 2013 | 1,528 |
| 2014 | 1,923 |
| 2015 | 4,815 |
| 2016 | 4,930 |
| 2017 | 6,885 |
| 2018 | 4,496 |
| 2019 | 4,735 |
| 2020 | 4,062 |
| 2021 | 3,694 |
| 2022 | 3,744 |
| 2023 | 3,527 |
| 2024 | 3,981 |
| 2025 | 3,972 |
| 2026 | 3,131 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Uzedy (Risperidone)
2024 spending
$65.3M
Beneficiaries
4,439
20,266 claims
Per beneficiary
$14,711
$9,293.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $9,765,799 |
| 2024 | $65,302,427 |
Part B: Uzedy (Risperidone) · HCPCS J2799
2024 spending
$100K
Beneficiaries
41
100 claims
Per beneficiary
$2,449
2024 ASP limit $24.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $100,391 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis.
Wang D, Schneider-Thoma J, Siafis S, et al. · Eur Neuropsychopharmacol 2024 · Systematic Review, Network Meta-Analysis
- Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis.
Krause M, Zhu Y, Huhn M, et al. · Eur Arch Psychiatry Clin Neurosci 2018 · Meta-Analysis, Systematic Review
- Antipsychotics for delirium.
Lonergan E, Britton AM, Luxenberg J, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Risperidone in children with autism and serious behavioral problems.
McCracken JT, McGough J, Shah B, et al. · N Engl J Med 2002 · Clinical Trial, Comparative Study
- Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment.
Choi H, Kim JH, Yang HS, et al. · Mol Autism 2024 · Meta-Analysis, Systematic Review
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.